GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SMO Clinplus Co Ltd (SZSE:301257) » Definitions » ROE %

SMO Clinplus Co (SZSE:301257) ROE % : 8.32% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is SMO Clinplus Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. SMO Clinplus Co's annualized net income for the quarter that ended in Mar. 2024 was ¥90.9 Mil. SMO Clinplus Co's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was ¥1,093.4 Mil. Therefore, SMO Clinplus Co's annualized ROE % for the quarter that ended in Mar. 2024 was 8.32%.

The historical rank and industry rank for SMO Clinplus Co's ROE % or its related term are showing as below:

SZSE:301257' s ROE % Range Over the Past 10 Years
Min: 12.26   Med: 29.34   Max: 56.3
Current: 12.69

During the past 7 years, SMO Clinplus Co's highest ROE % was 56.30%. The lowest was 12.26%. And the median was 29.34%.

SZSE:301257's ROE % is ranked better than
80.95% of 210 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.965 vs SZSE:301257: 12.69

SMO Clinplus Co ROE % Historical Data

The historical data trend for SMO Clinplus Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMO Clinplus Co ROE % Chart

SMO Clinplus Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial 53.74 24.34 29.34 12.26 13.26

SMO Clinplus Co Quarterly Data
Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.48 14.80 15.29 12.75 8.32

Competitive Comparison of SMO Clinplus Co's ROE %

For the Diagnostics & Research subindustry, SMO Clinplus Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SMO Clinplus Co's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's ROE % distribution charts can be found below:

* The bar in red indicates where SMO Clinplus Co's ROE % falls into.



SMO Clinplus Co ROE % Calculation

SMO Clinplus Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=134.73/( (951.968+1080.595)/ 2 )
=134.73/1016.2815
=13.26 %

SMO Clinplus Co's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=90.948/( (1080.595+1106.217)/ 2 )
=90.948/1093.406
=8.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


SMO Clinplus Co  (SZSE:301257) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=90.948/1093.406
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(90.948 / 738.132)*(738.132 / 1368.944)*(1368.944 / 1093.406)
=Net Margin %*Asset Turnover*Equity Multiplier
=12.32 %*0.5392*1.252
=ROA %*Equity Multiplier
=6.64 %*1.252
=8.32 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=90.948/1093.406
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (90.948 / 104.756) * (104.756 / 96.816) * (96.816 / 738.132) * (738.132 / 1368.944) * (1368.944 / 1093.406)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8682 * 1.082 * 13.12 % * 0.5392 * 1.252
=8.32 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


SMO Clinplus Co ROE % Related Terms

Thank you for viewing the detailed overview of SMO Clinplus Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


SMO Clinplus Co (SZSE:301257) Business Description

Traded in Other Exchanges
N/A
Address
No. 105 Sinan Road, Room 108, Building 1, Huangpu District, Shanghai, CHN, 200001
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
Executives
Lai Chun Bao Director
Ma Lin Director

SMO Clinplus Co (SZSE:301257) Headlines

No Headlines